| Christopher A. Viehbacher | President and CEO | FY2025 | |
| Susan H. Alexander | Executive Vice President, Chief Legal Officer | FY2025 | |
| Nicole C. Murphy | Head of Pharmaceutical Operations and Technology | FY2025 | |
| Priya A. Singhal | Head of Development | FY2025 | |
| Michael R. Mcdonnell | Executive Vice President, Chief Financial Officer | FY2024 | |
| Robin C. Kramer | Executive Vice President and Chief Financial Officer | FY2025 |
6 executives
Named executives and their total pay come from the Summary Compensation Table of the latest proxy statement.